Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611213 | 0.88 | CYP19A1 (0.37) | CYP19A1PDE2ASCN9AMEN1KMT2A | |
| SCHEMBL16754706 | 0.88 | CYP19A1 (0.37) | CYP19A1PDE2ASCN9AMEN1KMT2A | |
| SCHEMBL28003806 | 0.87 | PDE2A (0.35) | PDE2APRCPJAK2NTRK1MEN1 | |
| SCHEMBL17777222 | 0.85 | CYP19A1 (0.39) | CYP19A1JAK2NTRK1HDAC8HDAC6 | |
| SCHEMBL16613114 | 0.81 | CYP19A1 (0.42) | CYP19A1PDE2ASCN9AJAK2NTRK1 | |
| SCHEMBL16610725 | 0.81 | CYP19A1 (0.42) | CYP19A1PDE2ASCN9AJAK2NTRK1 | |
| SCHEMBL16754705 | 0.79 | PDE2A (0.42) | CYP19A1PDE2ASCN9AMEN1KMT2A | |
| SCHEMBL16610525 | 0.77 | CYP19A1 (0.40) | CYP19A1PDE2ASCN9AMEN1KMT2A | |
| SCHEMBL16610738 | 0.76 | KDM4E (0.37) | PDE2AHDAC8HDAC6 | |
| SCHEMBL16610630 | 0.76 | GSK3A (0.36) | CYP19A1JAK2NTRK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2857398-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | HRH4, CYP3A4, CYP3A5 | CYP19A1 761/4885PDE2A 1208/4885SCN9A 800/4885 |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | ROS1, NOX4, NOX3 | CYP19A1 2040/4885PDE2A 1397/4885SCN9A 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.